論文・総説​

​

・Sato N, Li W, Takemoto H, Takeuchi M, Nakamura A, Tokura E, Akahane C, Ueno K, Komatsu K, Kuriyama N, Onoda T, Higai K, Koike K. Comprehensive evaluation of antioxidant effects of Japanese Kampo medicines led to identification of Tsudosan formulation as a potent antioxidant agent. J Nat Med. 73(1):163-172. 2019. 

 

・ Obara K., Suzuki S., Shibata H., Yoneyama N., Hamamatsu S., Yamaki F., Higai K., Tanaka Y. Noradrenaline-induced relaxation of urinary bladder smooth muscle is primarily triggered through the β₃-adrenoceptor in rats. Biol. Pharm. Bull. 42(5):736-743 2019.

 

・Nagai H., Mukozu T., Kobayashi K., Amanuma M., Yoshimine N., Ogino YU., Matsui D., Daido Y., Matsukiyo Y., Matsui T., Wakui N., Momiyama K., Shinohara M., Higai K., Igarashi Y. Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology. Anticancer Res. 39(4):2183-2191 2019.

​

・Liu Q., Li W., Nagata K., Fu H., Okada S., Tanabe I., Kobori Y., Higai K., Norie W., Sasaki T., Asada Y., Zhao H., Bai H., Koike K.： Isolation, Structural Elucidation, and Liquid Chromatography–Mass Spectrometry Analysis of Steroidal Glycosides from Polygonatum odoratum, J. Agric. Food Chem., 66(2) 521-531, 2018. 

 

​

・Chino D., Sone T., Yamazaki K., Tsuruoka Y., Yamagishi R., Shiina S., Obara K., Yamaki F., Higai K., Tanaka Y., Pharmacological identification of β-adrenoceptor subtypes mediating  　isoprenaline-induced relaxation of guinea pig colonic longitudinal smooth muscle. J. Smooth Muscle Res. 54: 13–27, 2018. ​

 

・Zhang J., Li W., Sasaki T. Nagata K., Higai K., Feng F., Wang J., Cheng M., Koike K.: Identification of caffeoylquinic acid derivatives as natural protein tyrosine phosphatase 1B inhibitors from Artemisia princeps, Bioorganic & Medicinal Chemistry Letters, 28(7), 1194-1197, 2018. 

 

・ Kobayashi K., Higai K., Matsuo K.,　Bannai Y.,, Horie H., Otakara Y., Li W., Koike K., Yanagino S., Watanabe K., Yoshio T., Wakui N., Nagai H.: Quantitative measurements of sorafenib in patients with advanced hepatocellular carcinoma. International Journal of Research Studies in Medical and Health Sciences, 3(2), 14-19, 2018.

 

・Higai K., Otsuka N., Tanaka Y., Matsumoto K., Matsui M., Yanai K., Wakui N., Nagai H.: Sorafenib Decreases Dihydropyrimidine Dehydrogenase Gene Expression in Hepatocellular Carcinoma HepG2 Cells. Austin J Pharmacol Ther. 6(1).1102, 2018.

 

・Ito K., Kawana M., Iwata T., Higai K.: Transcriptional Regulation of the Natural Cytotoxicity Receptor NKp44 Gene in Human NK cell Leukemia. J of Glycomics Lipidomics 7:1, 2018.

 

・Ito K., Shiraishi R., Higai K.: Globo-A binds to the recombinant natural cytotoxicity receptor NKp44. Biol. Pharm. Bull., 41, 1480-1484, 2018. 

​

・Sato N, Li W, Tsubaki M, Higai K, Takemoto M, Sasaki T, Onoda T, Suzuki T, Koike K：Flavonoid glycosides from Japanese Camellia oil cakes and their inhibitory activity against advanced glycation end-products formation. Journal of Functional Foods, 35, 159–165, 2017.

​

・Onoda T, Li W, Sasaki T, Miyake M, Higai K, Koike K：Identification and evaluation of magnolol and chrysophanol as the principle protein tyrosine phosphatase-1B inhibitory compounds in a Kampo medicine, Masiningan, Journal of Ethnopharmacology 186 ,84–90, 2016. 

​

・Sasaki T., Li W., Higai K., Koike K.： Canthinone alkaloids are novel protein tyrosine phosphatase 1B inhibitors.Bioorg Med Chem Lett. 1;25(9):1979-1981 2015.

​

・Nagai H, Mukozu T, Ogino YU, Matsui D, Matsui T, Wakui N, Momiyama K, Igarashi Y, Sumino Y, Higai K: Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. Anticancer Res. 35(4):2269-2277 2015.

​

・Onoda T., Li W., Higai K, Koike K：Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents. BMC Complement Altern Med. 14:64. 2014. 

​

・Sasaki T., Li W., Higai K., Quang T., Kim Y.,2, Koike K.: Protein tyrosine phosphatase 1B inhibitory activity of lavandulyl flavonoids from roots of Sophora flavescens.  Planta Medica  80(07): 557-560 2014. 

​

・ Taniuchi F., Higai K., Tanaka T., Azuma Y.. Matsumoto K.: Transcriptional regulation of fucosyltransferase 1 gene expression in colon cancer cells. Scientific World Journal 105464 2013. 

​

・ Li W., Li S., Higai K., Sasaki T., Asada Y., Ohshima S., Koike K.：Evaluation of licorice flavonoids as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett. 1;23(21):5836-5839 2013. 

​

・Li D., Li W., Higai K, Koike K.：Protein tyrosine phosphatase 1B inhibitory activities of ursane- and lupane-type triterpenes from Sorbus pohuashanensis. J Nat Med., 68(2):427-431 2013.     

​

・Ito K., Higai K., Shinoda C., Sakurai M., Yanai K., Azuma Y., Matsumoto K. :Unlike NKp30, natural cytotoxicity receptor NKp44 binds to multimeric a2,3-NeuNAc-containing N-glycans. Biol. Pharm. Bull. 35 (4), 594-600 2012.

​

・ Higai K., Matsumoto K.: Glycan ligand specificity of killer lectin receptors. Yakugaku Zasshi. 132(6):705-712 2012.

​

・Higai K., Suzuki C., Imaizumi Y., Xin Xin, Azuma Y. and Matsumoto K: Binding affinities of NKG2D and CD94 to sialyl Lewis X-expressing N-glycans and heparin. Biol. Pharm. Bull. 34(1): 8-12 2011. 

​

・Xin X, Higai K., Imaizumi Y., Suzuki C.,Ito K., Itoh A., Matsumoto S., Azuma Y.,and Matsumoto K.: NKG2A and NKG2C bind to sulfated glycans and a2,3-NeuAc-containing glycoproteins.  Biol. Pharm. Bull. 34(4):480-485 2011.

​

・Ito K., Higai K., Sakurai M., Shinoda C., Yanai K., Azuma Y. and Matsumoto K.: Binding of Natural cytotoxicity receptor NKp46 to sulfate- and a2,3-NeuAc-containing glycans and its mutagenesis.  Biochem, Biophys. Res. Commun. 406 (3):377-382 2011.

​

・Higai K., Itoh A., Imaizumi Y., Suzuki C., Xin X., Azuma Y. and Matsumoto K.: Binding properties of CD94 to sulfated glycans and a2,3-NeuAc-containing glycoprotein and its mutagenesis analysis. The Open Biotechnology Journal, 5,14-20 2011.

​

・ Azuma Y, Nakagawa H, Dote K, Higai K and Matsumoto K: Decreases in CD31 and CD47 levels on the cell surface during etoposide-induced Jurkat cell apoptosis.  Biol. Pharm. Bull. 34 (12), 1828-1834 2011. 

​

​

・Higai K., Matsumoto S.,Kimura M.,Imaizumi Y.,Yanai K., Azuma Y., Matsumoto K.: NKG2D: Binding Properties for Glycan Ligands, and Mutagenesis Analysis. The Open Biotechnology Journal, 5,33-38 2011.

​

・ Higai K, Tsukada M., Moriya Y., Azuma Y., and Matsumoto K.: Prolonged culture in high glucose suppresses phorbol 12-myristate 13-acetate and ionomycin-induced interleukin-2 mRNA expression in Jurkat cells via accumulation of inducible cAMP early repressor. Biochim Biophys Acta. 1790 :8-15 2009. 

​

​

・ Imaizumi Y., Higai K., Suzuki C, Azuma Y, Matsumoto K.： NKG2D and CD94 bind to multimeric a2,3-linked N-acetylneuraminic acid. Biochem, Biophys. Res. Commun. 382:604-608 2009.

​

・ Higai K., Imaizumi Y., Suzuki C, Azuma Y. and Matsumoto K.: NKG2D and CD94 bind to heparin and sulfate-containing polysaccharides. Biochem, Biophys. Res. Commun. 386:709-714 2009.

​

・Sato H., Azuma Y., Higai K., Matsumoto K.: Altered expression of glycoproteins on the cell surface of Jurkat cells during etoposide-induced apoptosis: Shedding and intracellular translocation of glycoproteins. Biochimica et Biophysica Acta (BBA) - General Subjects, 1790 (10): 1198-1205 2009.

​

​

・Higai K, Satake M, Nishioka H, Azuma Y and Matsumoto K: Glycated human serum albumin enhances macrophage inflammatory protein-1b mRNA expression through protein kinase C-δ and NADPH oxidase in macrophage-like differentiated U937 cells. Biochim Biophys Acta. 1780 (2):307-314 2008.

​

・Higai K, Miyazaki N, Azuma Y and Matsumoto K: Transcriptional regulation of the fucosyltransferase VI gene in hepatocellular carcinoma cells. Glycoconj. J. (3):225-235 2008.

​

・Azuma Y, Kurusu Y, Sato H, Higai K, and Matsumoto K: Increased Expression of Lewis X and Y Antigens on the Cell Surface and FUT 4 mRNA during Granzyme B-Induced Jurkat Cell Apoptosis.  Biol. Pharm. Bull. 30(4) :655-660,2007.

​

・Azuma Y, Sato H, Higai K, and Matsumoto K: Enhanced expression of membrane-associated sialidase Neu3 decreases GD3 and increases GM3 on the surface of Jurkat cells during etoposide-induced apoptosis. Biol. Pharm. Bull. 30(9):1680-1684, 2007.

​

・Higai K, Sano R, Satake M, Azuma Y, and Matsumoto K: Glycated human serum albumin induced Interleukin 8 mRNA expression through reactive oxygen species and NADPH oxidase-dependent pathway in monocyte-derived U937 cells. Biol. Pharm. Bull. 30(10):1833-1837, 2007.

​

・Azuma Y, Miura K, Higai K, Matsumoto K: Protein O-N-acetylglucosaminylation modulates promoter activities of cyclic AMP response element and activator protein 1 and enhances E-selectin expression in HuH-7 human hepatoma cells. Biol Pharm Bull. 30(12) :2284-2289 2007.

​

・ Higai K, Ichikawa A, Matsumoto K: Binding of sialyl Lewis X antigen to lectin-like receptors on NK cells induces cytotoxicity and tyrosine phosphorylation of a 17-kDa protein. Biochim Biophys Acta. 1760(9):1355-1363, 2006.

​

・Higai K, Shimamura A, Matsumoto K: Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin. Chim. Acta 367 (1-2) 137-143, 2006.

​

・Higai K, Ishihara S, and Matsumoto K: Nuclear factor kB-p65-dependent transcriptional regulation of fucosyltransferase and sialyltransferase in human colon adenocarcinoma HT-29 cells. Biol. Pharm. Bull. （Highlighted paper selected by Editor-in-chief ）12:2372-2377,2006.

​

・ Higai K, Miyazaki N, Azuma Y and Matsumoto K: Interleukin-1b induces sialyl Lewis X on hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3Gal IV and FUT VI gene. FEBS lett., 580(26):6069-6075, 2006.

​

・Higai K, Aoki Y, Matsumoto K: Glycosylation of site-specific glycans of alpha(1)-acid glycoprotein and alterations in acute and chronic inflammation. Biochim Biophys Acta. 1725(1):128-135, 2005.

​

・Higai K, Shibukawa K, Muto S, Matsumoto K：Targeted proteo-glycomics analysis of sialyl Lewis X expressing glycoproteins secreted by HepG2 cells. Anal Sci 19(1):85-92, 2003. 

​

・Higai K, Azuma Y, Aoki Y, Matsumoto K: Altered glycosylation of a1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clin Chim Acta 329(1-2):117-125, 2003.

​

・Taniguchi A, Hasegawa Y, Higai K, Matsumoto K: Transcriptional regulation of human b-galactoside a2,6-sialyltransferase (hST6Gal I) gene during differentiation of the HL-60 cell line. Glycobiology 10(6):623-628, 2000.

​

・Taniguchi A, Hasegawa Y, Higai K, Matsumoto K: Down-regulation of human Galβ1,3 GalNAc/Galβ1,4GlcNAc α2,3-sialyltransferase (hST3Gal IV) gene during differentiation of the HL-60 cell line.  Mol Cell Biol Res Commun 2(3):197-201, 1999.

​

・Higai K, Masuda D, Matsuzawa Y, Satoh T, Matsumoto K：A fluorometric assay for glycosyltransferase activities using sugars aminated and tagged with 7-hydroxycoumarin-3-carboxylic acid as substrates and high performance liquid chromatography. Biol Pharm Bull 22(4):333-338, 1999. 

​

・Taniguchi A, Higai K, Hasegawa Y, Utsumi K, Matsumoto K: Differentiation elicits negative regulation of human β-galactoside α2,6-sialyltransferase at the mRNA level in the HL-60 cell line.  FEBS Lett 441(2):191-194, 1998.